Systemic anaplastic large cell lymphoma (sALCL), a PTCL subtype characterized by universal CD30 expression [3, 4], is therefore a candidate for CD30-targeted treatment. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.